In CLL, TCF7 expression provided a high rate (74%) of correct assignment of patients at genetic risk (IGHV unmutated, V3-21 usage, 11q-, or 17p-) (Kienle et al., 2010). This evidence concerns the gene TCF7 and B-cell chronic lymphocytic leukemia.